BioAge files for IPO, plans pair of midstage obesity trials

After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.

The Eli Lilly-partnered biotech hopes to list on the Nasdaq under the symbol “BIOA,” according to documents filed with the Securities and Exchange Commission. The company has not publicly shared an expected monetary amount for the offering.